Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

An Erratum to this article was published on 07 October 2014

Abstract

Summary

Bisphosphonates are the first-line treatment for osteoporotic (OP) women; however, therapy is not recommended in severe renal impairment (RI). This study examined RI prevalence among OP women. Nearly a quarter of women had moderate RI, and 3.59 % would not be recommended for bisphosphonates, demonstrating a need for better therapeutic alternatives.

Introduction

Bisphosphonates are the recommended first-line treatment for postmenopausal women with OP. However, bisphosphonates are cleared through the kidney, and therapy is not recommended in severe RI due to adverse treatment effects observed with intravenous formulations. The objective of this study was to examine the prevalence of RI among women with OP aged ≥50 years in the USA.

Methods

Women with OP aged ≥50 years were identified using the 2005–2008 National Health and Nutrition Examination Survey (NHANES) data. OP was defined as prior OP diagnosis, previous hip or spine fracture, or measured lumbar spine/femoral neck bone mineral density (BMD) T-score <−2.5. The 2005 Modification of Diet in Renal Disease (MDRD) formula was used to calculate the glomerular filtration rate (GFR). Moderate and severe RI was defined as GFR 30–59 and 15–29 mL/min, respectively. Bisphosphonate therapy was considered not recommended among women with OP if GFR was <35 mL/min.

Results

The prevalence of OP among women in USA aged ≥50 years was 27 % (12.7 million). Nearly a quarter of women with OP (23.54 ± 2.02 %; 2.9 million) had moderate RI and 1.88 ± 0.28 % (230,000) had severe RI. Correspondingly, bisphosphonate therapy would not be recommended for an estimated 439,000 women with OP (3.59 ± 0.73 %).

Conclusions

Nearly a quarter of postmenopausal women with OP have moderate RI, and over 3 % would not be recommended for bisphosphonate treatment. These data reveal a need for better therapeutic alternatives that can be used in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008. Osteoporos Int 23(3):811–820. doi:10.1007/s00198-011-1694-y

    Article  PubMed  CAS  Google Scholar 

  2. Looker AC, Melton LJ III, Harris TB, Borrud LG, Shepherd JA (2010) Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res 25(1):64–71. doi:10.1359/jbmr.090706

    Article  PubMed  PubMed Central  Google Scholar 

  3. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815–2822

    Article  PubMed  CAS  Google Scholar 

  4. Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, Hanley DA, Kreiger N, Josse R, Papaioannou A, Olszynski WP, Jamal SA (2009) Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res 24(9):1515–1522. doi:10.1359/jbmr.090319

    Article  PubMed  Google Scholar 

  5. National Osteoporosis Foundation (2010) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed 12 Feb 2013

  6. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124

    Article  PubMed  CAS  Google Scholar 

  7. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analysis of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517–523

    Article  PubMed  CAS  Google Scholar 

  8. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189–1199. doi:10.1056/NEJMoa030897

    Article  PubMed  CAS  Google Scholar 

  9. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312

    Article  PubMed  CAS  Google Scholar 

  10. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941

    Article  PubMed  CAS  Google Scholar 

  11. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80(5):225–230

    Article  PubMed  CAS  Google Scholar 

  12. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.1210/jc.2012-1027

    Article  PubMed  CAS  Google Scholar 

  13. Miller PD (2011) The kidney and bisphosphonates. Bone 49(1):77–81. doi:10.1016/j.bone.2010.12.024

    Article  PubMed  CAS  Google Scholar 

  14. Sadowski CA, Spencer T, Yuksel N (2011) Use of oral bisphosphonates by older adults with fractures and impaired renal function. Can J Hosp Pharm 64(1):36–41

    PubMed  PubMed Central  Google Scholar 

  15. (2012) Fosamax [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.

  16. Federal Food and Drug Administration (FDA) (2011) FDA Drug Safety Communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 15 May 2012

  17. (2011) Boniva [package insert]. San Francisco, CA: Genentech, Inc.

  18. (2012) Actonel [package insert]. North Norwich, NY: Norwich Pharmaceuticals, Inc.

  19. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES) 2007–2008 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/generaldoc_e.htm. Accessed: May 8, 2012

  20. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2005) National Health and Nutrition Examination Survey (NHANES) 2005–2006 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/general_data_release_doc_05_06.pdf. Accessed: May 8, 2012

  21. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—femur bone measurements. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/DXXFEM_D.htm. Accessed 8 May 2012

  22. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—femur. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/DXXFEM_E.htm Accessed 8 May 2012

    Google Scholar 

  23. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/DXXSPN_D.htm. Accessed 8 May 2012

  24. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry—spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/DXXSPN_E.htm. Accessed 8 May 2012

  25. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761–1768. doi:10.1359/jbmr.1997.12.11.1761

    Article  PubMed  CAS  Google Scholar 

  26. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468–489

    Article  PubMed  CAS  Google Scholar 

  27. Kelly TJ (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5(Suppl 1):S249

    Google Scholar 

  28. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007–2008 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007–2008/ALB_CR_E.htm Accessed 15 May 2012

    Google Scholar 

  29. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2007) National Health and Nutrition Examination Survey (NHANES): 2005–2006 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005–2006/ALB_CR_D.htm Accessed 15 May 2012

  30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

    Article  PubMed  PubMed Central  Google Scholar 

  31. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137–147

    Article  PubMed  Google Scholar 

  32. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1):S1-266

    Google Scholar 

  33. Thorp ML, Eastman L, Smith DH, Johnson ES (2006) Managing the burden of chronic kidney disease. Dis Manag 9(2):115–121. doi:10.1089/dis.2006.9.115

    Article  PubMed  Google Scholar 

  34. World Health Organization (2011) Global Database on Body Mass Index (BMI): BMI Classification. United Nations. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed 8 May 2012

  35. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2005–2006 by Age and Gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0506MF.pdf. Accessed 8 May 2012

  36. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2007–2008 by age and gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0708MF.pdf. Accessed 8 May 2012

  37. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (1996) Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988–94). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes3/nh3gui.pdf Accessed 8 Nov 2013

    Google Scholar 

  38. Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20(3):186–190. doi:10.1111/j.1525-139X.2007.00271.x

    Article  PubMed  Google Scholar 

  39. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503–508. doi:10.1359/jbmr.070112

    Article  PubMed  CAS  Google Scholar 

  40. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105–2115. doi:10.1359/jbmr.050817

    Article  PubMed  CAS  Google Scholar 

  41. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74(5):641–648. doi:10.1038/ki.2008.193

    Article  PubMed  CAS  Google Scholar 

  42. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:138

    Google Scholar 

  43. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (113):S1-130. doi:10.1038/ki.2009.188

  44. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28(10):2049–2059. doi:10.1002/jbmr.2058

    Article  PubMed  CAS  Google Scholar 

  45. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3 years progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16(2):184–190. doi:10.1007/s00198-004-1662-x

    Article  PubMed  CAS  Google Scholar 

  46. Hill JA, Goldin JG, Gjertson D, Emerick AM, Greaser LD, Yoon HC, Khorrami S, Aziz D, Adams JS (2002) Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 9(10):1148–1152

    Article  PubMed  Google Scholar 

  47. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493

    Article  PubMed  CAS  Google Scholar 

  48. Centers for Disease Control and Prevention (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56 (8):161–165

    Google Scholar 

  49. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ (2008) CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51(4 Suppl 2):S13–20. doi:10.1053/j.ajkd.2007.12.016

    Article  PubMed  CAS  Google Scholar 

  50. Zimmerman SI, Girman CJ, Buie VC, Chandler J, Hawkes W, Martin A, Holder L, Hebel JR, Sloane PD, Magaziner J (1999) The prevalence of osteoporosis in nursing home residents. Osteoporos Int 9(2):151–157

    Article  PubMed  CAS  Google Scholar 

  51. Center for Drug Evaluation and Research (CDER) (2010) Guidance for industry: Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 24 May 2013

Download references

Acknowledgements

None.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Epidemiology, Merck & Co Inc, New Jersey, USA

    R. Lubwama & A. Nguyen

  2. Global Health Outcomes, Merck & Co Inc, New Jersey, USA

    A. Modi

  3. Health Policy and Management, University of North Carolina, Chapel Hill, USA

    C. Diana

  4. Colorado Center for Bone Research, Lakewood, USA

    P. D. Miller

Authors
  1. R. Lubwama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Modi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Diana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. D. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Lubwama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lubwama, R., Nguyen, A., Modi, A. et al. Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option?. Osteoporos Int 25, 1607–1615 (2014). https://doi.org/10.1007/s00198-014-2645-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2645-1

Keywords

Search

Navigation